Review CalOptima Health’s Vaccine Guidance Following Updated CDC Recommendations | |
On January 5, 2026, the Centers for Disease Control and Prevention (CDC) released a revised childhood and adolescent immunization schedule that changes recommendations for several vaccines. Key changes include:
- Hepatitis A and B, rotavirus, influenza, meningococcal disease and COVID-19 vaccines are no longer routinely recommended.
- DTaP, Hib, Pneumococcal, Polio, MMR, varicella and HPV (now one dose instead of two) vaccines are still recommended routinely for all children.
- Rotavirus, hepatitis A and B, and meningococcal ACWY and B vaccines are recommended for high-risk children.
- Rotavirus, COVID-19 and influenza vaccines are recommended for shared decision-making.
The American Academy of Pediatrics (AAP) and the American Academy of Family Physicians (AAFP) have not endorsed the revised CDC recommendations and have issued their own immunization guidelines that differ from the CDC’s. The California Department of Public Health (CDPH) will not adopt the new CDC childhood vaccine recommendations but will maintain its comprehensive immunization schedule, aligning with the AAP and AAFP.
We remain committed to evidence-based practices. We will continue to follow evidence-based immunization guidelines from AAP and AAFP, in alignment with CDPH guidance, to ensure the highest standard of care for children, young adults and families.
Please note that all vaccines, regardless of category, will remain covered at no cost under private and public insurance, including Affordable Care Act plans, Medicaid, the Children’s Health Insurance Program (CHIP) and the Vaccines for Children program. California Assembly Bill 144 ensures that vaccines recommended by the CDPH as of January 1, 2025, will continue to be covered by insurance in California, despite federal changes.
What does this mean for you?
- Continue to recommend and administer childhood and adolescent vaccines per AAP guidance and for young adults 19 years or older per AAFP guidance.
- Communicate clearly with families about benefit coverage and safety.
- Performance accountability for the HEDIS immunization measures, including Childhood Immunization Status and Immunizations for Adolescents, remains unchanged.
Providers who follow immunization guidelines in accordance with CDPH guidelines based on AAP and AAFP vaccination guidelines are provided liability protection.
| | | Hospice Providers Encouraged to Review Eligibility, Documentation and Claims Policies | |
Effective July 1, 2025, we aligned our hospice service policies with the Department of Health Care Services (DHCS) All Plan Letter (APL) 25-008. We encourage all our contracted hospice providers to review the following policies:
1. Hospice In-Network Provider Participation Requirements — We require members in need of hospice services to use participating hospice providers listed in our online Provider Directory, unless medically necessary services are unavailable in-network.
Members may request hospice services by:
- Contacting their primary care provider (PCP) or treating physicians
-
Call CalOptima Health Customer Service at 888-587-8088 for Medi-Cal and 877-412-2734 for OneCare (HMO D-SNP), a Medicare Medi-Cal Plan.
Hospice providers must:
- Maintain Medicare certification for hospice services
- Hold a valid CDPH license
- Be enrolled in Medi-Cal and have a National Provider Identifier (NPI)
2. Required Documentation for Approval and Payment of Hospice Services —Participating hospice providers must submit all necessary documents to us for each benefit period (two initial 90-day periods and subsequent 60-day periods).
3. Documentation Submission — Fax the following documents to 714-246-8843 (for more information, please see the document grid here):
-
DHCS Hospice Election Notice (NOE) that is properly completed and submitted within five calendar days of initial certification and election of hospice care services.
- Hospice Certification of Terminal Illness.
- CalOptima Health Hospice Notification Form (HNF)
- A written plan of care that was established by the attending physician, medical director or physician designer, and the interdisciplinary group prior to providing care.
- Face-to-Face Encounter Attestation. Starting with the third benefit period, a hospice physician or nurse practitioner must confirm a face-to-face encounter within 30 days prior to the benefit period.
4. Claims Payment — In instances where the hospice provider does not submit the election form within five days of admission to hospice services, we are not obligated to cover days of hospice care from the hospice admission date to the date the election form is submitted and accepted by us. These noncovered days are a hospice provider’s liability, and the hospice provider cannot bill the member for them.
Payment and/or coverage for hospice care services may be denied if, based on documentation, it is determined that the services are not medically necessary or the member is not terminally ill, with liability placed on the hospice provider. We will conduct utilization reviews to confirm hospice eligibility and may request additional records at any time.
For questions or clarification regarding our hospice policies, please contact our Long-Term Services and Supports department by calling 714-246-8600, faxing 714-246-8843 or emailing ltsscommunication@caloptima.org.
| CEO Michael Hunn to Retire at the End of 2026 | |
CalOptima Health Chief Executive Officer Michael Hunn has announced that he will retire on December 31, 2026. As the health plan’s leader for the past five years, Hunn has been deeply committed to serving low-income and vulnerable populations and supporting the health care safety net. Hunn’s focus on putting members at the center of the organization contributed to CalOptima Health’s growth, increased employee and provider engagement, and brought positive recognition among public health plans.
Hunn’s provider-focused accomplishments include enacting multiple rate increases that benefited safety net providers and hospitals, expanding access to care by adding Providence as a 10th health network, creating Street Medicine programs in four cities across Orange County and implementing workforce development grants to reduce provider shortages.
“I am proud of everything we have achieved at CalOptima Health over the past five years, and I will remain fully committed and focused through the end of the year,” Hunn said. “We have reinvigorated CalOptima Health and reestablished our plan as a trusted community partner that serves members with dignity and respect.” Hunn joined CalOptima Health as interim CEO in November 2021 and was named CEO in 2022.
| | | DHCS Shares Managed Care Accountability Set Requirements for 2026 | |
On December 22, 2025, DHCS shared the Managed Care Accountability Set (MCAS) requirements for Measurement Year (MY) 2026 and Reporting Year (RY) 2027.
The MCAS is a set of performance measures DHCS selects for annual reporting by managed care plans (MCPs) to assess quality and health equity efforts. Current and prior year MCAS lists can be found here.
The list of high-level updates to the MCAS requirements includes the following:
- RY 2027 includes 21 measures, compared to 31 in RY 2026
- Six administrative, five hybrid/administrative and 10 electronic clinical data systems
- Long-term care (LTC)-specific and opioid-related measures were eliminated
- Prenatal and postpartum depression screenings moved to Minimum Performance Level (MPL) status
| | | GLP-1 Therapy Could Help Your Patients With Diabetes and Weight Management | |
The 2026 American Diabetes Association (ADA) Standards of Care emphasize obesity as a key driver of Type 2 diabetes and related complications. Effective weight management improves glycemic control, reduces medication needs and can even lead to remission. Among available strategies, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and the dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 RA and tirzepatide stand out for their dual benefits of lowering blood glucose and promoting meaningful weight loss.
Why GLP-1 Therapy Matters
GLP-1 RAs (e.g., semaglutide, liraglutide) and tirzepatide are preferred for individuals with Type 2 diabetes who are overweight or obese. Clinical trials show that weekly injections of 2.4 mg of semaglutide can achieve approximately 9.6% weight loss, while tirzepatide can deliver up to 14.7% weight loss over 72 weeks — far exceeding traditional therapies. These agents also improve cardiovascular risk factors and may benefit conditions like fatty liver disease and sleep apnea.
Key Considerations
Providers should monitor patients for gastrointestinal side effects, adjust insulin or sulfonylurea doses as needed to prevent hypoglycemia, and titrate doses gradually to improve tolerability. Please note that obesity is a chronic condition and discontinuing therapy often leads to weight regain and reversal of benefits. The ADA recommends continuing treatment beyond initial goals and monitoring for nutritional deficiencies, particularly vitamin D deficiency.
GLP-1–based therapies are a cornerstone of modern diabetes care. Shared decision-making, ongoing monitoring and patient education are essential for long-term success.
Clinical Tips for Providers
- Start low, go slow: Gradual titration improves tolerability
- Adjust other meds: Reduce insulin/sulfonylurea to avoid hypoglycemia
- Monitor nutrition: Screen for vitamin D and micronutrient deficiencies
- Counsel on GI effects: Educate on managing nausea and diet changes
- Plan for maintenance: Continue therapy beyond weight loss goals
You can review the full ADA Standards of Care here.
| | | As of January 1, 2026, we have updated the Utilization Management (UM) Turnaround Time (TAT) Medi-Cal and OneCare grids to align with the Centers for Medicaid & Medicare Services (CMS) Final Rule requirements. Under the Final Rule, the routine/standard decision and notification TAT for both Medi-Cal and OneCare has been changed to seven calendar days. CalOptima Health policies GG.1507 Notification Requirements for Covered Services Requiring Prior Authorization and GG.1508 Authorization and Process of Referrals have been updated to align with the CMS Final Rule. | ABA Services Do Not Require Rediagnosis | We are reminding our contracted providers that CalOptima Health does not require rediagnosis for pervasive developmental disorder or autism to maintain coverage for behavioral health treatment, per Health and Safety Code § 1374.73. Applied Behavior Analysis (ABA) services also do not require rediagnosis, in alignment with the provisions of Assembly Bill 951. | | | Follow These Best Practices to Avoid Prescribing Unnecessary Antibiotics | |
According to the CDC, approximately 80% to 90% of antibiotic prescriptions are written in outpatient settings, and at least 28% of those antibiotics are unnecessary. Because most causes of upper respiratory tract infections are viral, the CDC advises against prescribing antibiotics for acute bronchitis or bronchiolitis in otherwise healthy individuals.
The Avoidance of Antibiotic Treatment for Acute Bronchitis/Bronchiolitis (AAB) Healthcare Effectiveness and Data Information Set (HEDIS) measure examines the percentage of episodes for members ages 3 months and older with a diagnosis of acute bronchitis or bronchiolitis that did not result in an antibiotic dispensing event.
Common ICD-10-CM Diagnosis Codes
For inclusion:
- Acute bronchitis — J20.3, J20.4, J20.5, J20.6, J20.7, J20.8, J20.9
- Acute bronchiolitis — J21, J21.1, J21.8, J21.9
For exclusion:
- Acute pharyngitis — J02
- Acute tonsillitis — J03
- Suppurative otitis media — H66
- Acute sinusitis — J01
- Pneumonia — J18
- Chronic sinusitis — J32
- Chronic tonsillitis; hypertrophy tonsils — J35
- Disease upper respiratory tract — J39
- Cellulitis/acute lymphangitis — L03
- UTI — N39
Exclusions:
- Members in hospice or using hospice services anytime during the measurement year.
- Members who died anytime during the measurement year.
How can I improve performance?
- Document correct ICD‑10-CM diagnosis codes for acute bronchitis and bronchiolitis.
- Avoid the use of antibiotics for routine treatment of uncomplicated acute bronchitis or bronchiolitis.
- If an antibiotic prescription is needed due to the patient having a coexisting bacterial infection (e.g., otitis media, sinusitis, pneumonia) or a comorbid condition (e.g., chronic obstructive pulmonary disorder [COPD], HIV, cancer), make sure to document and code for the bacterial infection and/or comorbid condition on the same claim.
Tips and Trainings:
- If a patient insists on an antibiotic:
- Refer to the illness as a chest cold rather than bronchitis, as patients tend to associate the label with a less‑frequent need for antibiotics.
- Educate the patient that antibiotics do not work against viruses that cause most chest colds or bronchitis.
- Suggest medications for symptom relief, such as guaifenesin/dextromethorphan for an antitussive (covered by Medi-Cal Rx with a prescription).
- Training and continuing education opportunities:
-
Free courses are available through the Stewardship Training Course
-
Free online seminar on Improving Antibiotic Use for Acute Respiratory Infections (one AAFP credit)
| | | Use These Best Practices When Prescribing Antibiotics for Children With Pharyngitis | |
To help providers improve their performance on the Testing for Children with Pharyngitis (CWP) HEDIS measure, we are sharing the following tips.
The CWP measure covers the percentage of episodes among members 3 years old and older who were diagnosed with pharyngitis and dispensed an antibiotic and who also received a group A streptococcus (strep) test for that episode.
Best practice is to always perform a rapid strep test or throat culture to confirm a diagnosis of strep pharyngitis before prescribing antibiotics. Clinical findings alone do not adequately distinguish strep from non-strep pharyngitis. Other best practices include:
- Do not treat “red throats” empirically with antibiotics, since most cases are viral.
- Educate parents/caregivers on the difference between bacterial and viral infections and that antibiotics are not necessary for viral infections.
-
Write a prescription for over-the-counter medications for symptom relief, like throat sprays or lozenges. The CDC has a Symptom Relief Prescription Pad, which can be downloaded from cdc.gov.
- If antibiotics are prescribed for another condition or illness, make sure to document the condition and submit diagnosis codes that apply on the claim or encounter.
Codes Included in the Current HEDIS Measure
Pharyngitis — ICD-10 codes: Streptococcal Sore Throat J02.0; Acute Pharyngitis J02.8; J02.9; Acute Tonsillitis J03.00, J03.01, J03.80, J03.81, J03.90, J03.91
Group A Strep Tests — CPT codes 87070, 87071, 87081, 87430, 87650–87652, 87880
The following antibiotic medications, in conjunction with a strep test (rapid strep test or throat culture), will meet compliance for this measure:
- Aminopenicillins — Amoxicillin, Ampicillin
- Beta-lactamase inhibitors — Amoxicillin-clavulanate
- First-generation cephalosporins — Cefadroxil, Cefazolin, Cephalexin
- Folate antagonist — Trimethoprim
- Lincomycin derivatives — Clindamycin
- Macrolides — Azithromycin, Clarithromycin, Erythromycin
- Natural penicillin — Penicillin G benzathine, Penicillin G potassium, Penicillin G sodium, Penicillin V potassium
- Quinolones — Ciprofloxacin, Levofloxacin, Moxifloxacin, Ofloxacin
- Second-generation cephalosporins — Cefaclor, Cefprozil, Cefuroxime
- Sulfonamides — Sulfamethoxazole-trimethoprim
- Tetracyclines — Doxycycline, Minocycline, Tetracycline
- Third-generation cephalosporins — Cefdinir, Cefixime, Cefpodoxime, Ceftriaxone
Required Exclusions
- Members who use hospice services or elect to use a hospice benefit any time during the measurement period.
- Diagnosis of comorbid conditions (e.g., HIV, cancer, immunodeficiency) either 12 months prior to or on the episode date.
- Visits that result in inpatient stay.
| | | Updated DHCS Community Supports Guidance Includes Transitional Rent | |
On January 16, 2026, DHCS distributed an updated Community Supports Member Information Sharing Guidance to reflect the launch of Transitional Rent.
The guidance now includes the following three Transitional Rent data elements that were added to the Enhanced Care Management/Community Supports/Complex Care Management JavaScript Object Notation (JSON) Exchange v4.3 guidance in October 2025:
- Transitional Rent Population of Focus
- Household Size
- Last Date of Service
As communicated to MCPs during the November MCP Technical Assistance call, JSON is one of three mechanisms DHCS uses as part of its comprehensive approach for MCP reporting on Transitional Rent utilization and outcomes. In addition to JSON, DHCS expects MCPs to share Transitional Rent data through monthly encounters and the Capitated Rates Development Division (CRDD) Supplemental Payment Reporting for Transitional Rent.
| DHCS Releases Community Supports Pricing Resource Addendum | |
On December 30, 2025, DHCS shared the Community Supports Pricing Resource, an addendum to the 2021 Non-Binding Community Supports Pricing Resource.
The addendum updates the Community Supports program by refining service definitions and billing guidance. Specifically, this update includes pricing benchmarks (based on August 2021 data) and HCPCS codes with modifiers for newly defined subservices, as outlined in the 2025 Community Supports Policy Guide, Volume 1. All services included in the addendum are listed below:
- Assisted Living Facility Transitions
- Transition services and expenses
- Ongoing assisted living services
- Community or Home Transition Services
- Nonrecurring setup expenses
- Medically Tailored Meals/Medically Supportive Food
- Medically supportive groceries
- Produce prescription
- Healthy food voucher
- Food pharmacy
- Nutrition education
To maintain consistency with the original 2021 Community Supports Non-Binding Pricing Resource, the new pricing benchmarks are based on data and assumptions most relevant to August 2021 to create a “2021 benchmark range.” This is an interim step as DHCS works toward a comprehensive update of pricing benchmarks for all Community Supports services.
Where possible, the addendum lists more recent supplemental pricing information from California and other states’ programs as a resource to MCPs and providers. However, the benchmark ranges do not take this more recent information into account.
DHCS is also reminding MCPs that this resource is nonbinding. MCPs and Community Supports providers have full discretion to negotiate prices and payment methodologies that reflect providers’ unique staffing models, regional costs, service intensity, population risk mix, quality of care and other considerations, including prices outside of the provided ranges. The Community Supports Policy Guide, Volume 1, will be updated soon with the HCPCS codes and modifiers for the newly defined and distinguished subservices included in the addendum.
| MY 25 MCAS County-Level Reporting Requirements Now Available | |
On January 8, 2026, DHCS distributed the MY 2025 MCAS county-level reporting requirements to MCPs.
DHCS built upon the MY 2024 framework and incorporated the following updates:
- Revised general instructions for data submission
- Clarified reporting methodologies to reduce discrepancies in county-level rates
- Clarified minimum and maximum denominators for hybrid measures
- Introduction of an attestation process to verify submitted data, which will be included in the MY 2025 Rate Reporting Template (RRT)
County-level submissions are due to DHCS on July 3, 2026.
| | | -
On January 7, 2026, DHCS distributed APL 26-001: Initial Health Appointment to MCPs. The purpose of the APL is to provide guidance to MCPs regarding the requirements of the Initial Health Appointment (IHA) beginning January 1, 2023. This APL supersedes APL 22-030.
| |
Based on Medi-Cal Bulletins and NewsFlashes, CalOptima Health has updated the procedure codes and other relevant information for the subjects listed below:
- 2026 HCPCS Quarter 1 Update
- ICD-10-CM Diagnosis Codes for Intimate Partner Violence
- CPT Code 38228 Rate Update for CAR-T Services
- Update for Select ICD-10-CM/PCS Codes for Quarterly 2024
- Update: Children’s Presumptive Eligibility Worksheet
- Global Obstetrical Billing Update
- PLA Codes 0402U and 0455U Updated to Medi-Cal Benefits
- Documentation Requirements Changed for Prenatal Screen Follow-Up and Diagnostic Testing Services
- PLA Codes 0134U and 0356U Are Medi-Cal Benefits
- Select Biomarker Testing PLA Codes Are Now Medi-Cal Benefits
- Medi-Cal Provider Training Webinars for January and February 2026
- Provider Manual Revisions
- Updated Reimbursement Requirements for Select Psychiatric Hospital Services
- 2026 Distinct-Part Pediatric Subacute Facilities Reimbursement Rate Update
- 2026 Freestanding Pediatric Subacute Facilities Reimbursement Rate Update
- CPT Code 87626 Is a Family PACT Benefit
- HCPCS Codes A4295, A4296 and A4297 Added as Medi-Cal Benefits
- National Correct Coding Initiative Quarterly Update for January 2026
- Skilled Nursing Facility Accountability Sanctions Program Policy
- Reimbursement Rate Rescinded for HCPCS Code S5552
For detailed information regarding these changes, please refer to: General Medicine Bulletin 619, Inpatient Services Bulletin 616, Long Term Care Bulletin 587, Family PACT Bulletin 220, and Medi-Cal NewsFlashes from December 16, December 23, January 13 and January 14.
To access the updated Physician Administered Drug Prior Authorization List (PAD PA List), please refer to: www.caloptima.org/en/ForProviders/ClaimsandEligibility/PriorAuthorizations.aspx.
| Policies and Procedures Monthly Update | |
Click on the link below to find an outline of changes made to CalOptima Health policies and procedures during January 2025. The full description of the policies below is available on CalOptima Health’s website at:
www.caloptima.org/for-providers/provider-resources/manuals-policies-and-guides
Policies and Procedures Monthly Update
| | | Health Education: Training and Meetings | |
Click below for training webinars and meetings happening in February 2025:
Health education webinars
|
- CalOptima Health Board of Directors: February 5 at 2 p.m.
- Joint Meeting of the Provider and Member Advisory Committees: February 11 at Noon
All meetings have an option for virtual attendance. Visit the CalOptima Health website for more information.
| | | Follow Us on Social Media | | | CalOptima Health regularly posts on social media to engage members with health tips, community resources, event dates, program updates and other pertinent information. Follow us on Facebook, Instagram, X and LinkedIn. | | |
CalOptima Health, A Public Agency www.caloptima.org
| |
| | | |